Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas
Prolonged complete remissions (CRs) are rare in advanced-stage cutaneous T-cell lymphomas (CTCLs). Ifosfamide + etoposide (I+E) have been used to treat lymphomas, combined with platinum-based agents in Hodgkin disease or non-Hodgkin lymphomas including peripheral T-cell lymphomas. Monoclonal antibodies have induced long-term remissions in CTCL but are usually poorly effective in transformed disease Allogeneic haematopoietic stem cell transplantation (alloHSCT) holds a potential for cure but relies on the existence of a pretransplant CR, which may require the use of chemotherapeutic regimens.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Adele de Masson, Ambre Dangien, Caroline Ram-Wolff, Maxime Battistella, H élène Moins-Teisserenc, Martine Bagot Tags: ORAL PRESENTATIONS: TREATMENTS Source Type: research
More News: Cancer | Cancer & Oncology | Cutaneous T cell lymphoma | Hodgkin's Disease | Lymphoma | Oral Cancer | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants